An Incisive, In-depth Analysis on the Dengue Vaccines Market
This study offers a comprehensive, 360 degree analysis on the Dengue Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Dengue Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Global dengue vaccine market revenue is expected to expand at a significant rate owing to a large unmet need
The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur is registered in 14 countries in the Latin America and Asia Pacific region. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine that is indicated as a 3 dose series of 0/6/12 month schedule. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines as well as subunit, DNA and purified inactivated vaccine candidates of which Takeda’s TAK-003 and Butantan Institute vaccine candidates are being evaluated in phase 3 clinical trials currently.
The global dengue vaccine market is estimated to be valued at nearly US$ 250 Mn in 2017 and is expected to expand at a 17.5% CAGR over the forecast period (2017–2027). The global dengue vaccine market is projected to be valued at more than US$ 1250 Mn by 2027.
Factors impacting the global dengue vaccine market
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine, and expected local production of dengue vaccine in various countries. Other prominent factors driving revenue growth of the market are adoption/uptake of dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governmental interest to incorporate the vaccine in public immunisation programmes across various countries.
However, supply side infrastructure bottlenecks such as surveillance system, standardised diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countries are the factors hampering the growth of the global dengue vaccine market.
Companies engaged in the development of dengue vaccine are employing strategies to incorporate dengue vaccine in public immunisation programmes and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Global Dengue Vaccine Market Attractiveness Analysis by End User, 2017 – 2027
Several governments are willing to incorporate dengue vaccine in public immunisation programmes given assured quality, safety and affordability of the vaccine in endemic countries
The Government Institutes segment is expected to dominate the global dengue vaccine market in revenue terms and the trend is projected to continue throughout the forecast period. The Government Institutes segment is estimated to account for 49.5% value share in 2017 and is projected to account for 51.9% share by the end of 2027. In terms of value, the Hospitals segment is anticipated to register a moderate CAGR of 17.3% during the forecast period. The NGOs segment is expected to remain the least attractive segment in the global dengue vaccine market in revenue terms with an attractiveness index of 0.7 over the forecast period. The NGOs segment is estimated to account for 22.5% value share in 2017 and is projected to account for 20.5% value share by the end of 2027.
Developing a vaccine that is effective in all age groups is expected to drive market revenue growth over the forecast period
Of late dengue vaccine candidates, which are in the late stage of development, are showing better clinical benefits in all age groups and have better dosing pattern. For instance, Takeda’s - Tak-003 dengue vaccine candidate has demonstrated acceptable safety and efficacy in different population groups with two doses (three months apart) of vaccine. Currently Dengvaxia is recommended in three doses at 0, 6, 12 months. Development of dengue vaccine that is effective for infants and children is expected to reduce the dengue burden and thereby create demand in the global dengue vaccine market.
Future Market Insights in its report titled “Dengue Vaccine Market: Global Industry Analysis and Opportunity Assessment, 2017–2027” offers detailed insights and in-depth research on the global dengue vaccine market over a 10 year forecast period 2017 – 2027. The report covers the important factors driving the growth of the global dengue vaccine market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the global dengue vaccine market and other insights across various key segments. The report identifies the drivers and restraints affecting the growth of the global dengue vaccine market. Changing trends are also analysed and incorporated in the report to provide exhaustive information about the market resulting in better decision making. Macroeconomic factors and forecast factors that directly and indirectly affect the growth of the global dengue vaccine market are also incorporated in the report.
The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global dengue vaccine market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies developing the dengue vaccine in the global dengue vaccine market are presented in the report. To understand and assess opportunities in this market, the report offers market forecast on the basis of end user and regions. The report provides analysis of the global dengue vaccine market in terms of market value (US$ Mn).
The report begins with the market introduction followed by the global market overview of the dengue vaccine. The market dynamics section includes Future Market Insights’ analysis of key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global dengue vaccine market. The report also analyses various issues of Dengvaxia, tiered pricing of dengue vaccine, sales channel strategy adoption, pipeline assessment, promotional activities adopted by Sanofi, and epidemiology of dengue.
By End User
In the final section of the report, a competitive landscape has been included to provide a dashboard view of key companies operating in the global dengue vaccine market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global dengue vaccine market and the potential players. This section also includes market strategies and SWOT analysis of the main players operational in the global dengue vaccine market.
We have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the global dengue vaccine market and to identify growth opportunities for companies operating in the global dengue vaccine market. Another important feature of our report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity analysis is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered in the global dengue vaccine market. Furthermore, to understand key market segments in terms of their growth and performance in the global dengue vaccine market, Future Market Insights has developed a unique market attractiveness index to help providers identify existing market opportunities.
The various sub segments of the global dengue vaccine market have also been analysed in terms of Basis Point Share (BPS) to understand individual segments’ relative contribution to market growth. This detailed level of information is important for identifying various key trends in the global dengue vaccine market.
Dengue Vaccines Market Reports - Table of Contents
1. Executive Summary
10. Rest of the World (RoW) Dengue Vaccine Opportunity Analysis and Forecast
12. Assumptions and Acronyms Used
13. Research Methodology